Capital Research Global Investors Has $301.82 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Capital Research Global Investors increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,535,854 shares of the medical research company’s stock after buying an additional 3,193 shares during the period. Capital Research Global Investors owned 0.85% of IQVIA worth $301,817,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at $33,000. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. acquired a new position in IQVIA during the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. boosted its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after buying an additional 85 shares during the period. Finally, Versant Capital Management Inc grew its stake in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. lowered their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Robert W. Baird lowered their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Finally, Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $241.50.

IQVIA Stock Down 3.2 %

NYSE IQV opened at $143.66 on Friday. The stock’s 50 day simple moving average is $176.42 and its 200 day simple moving average is $196.62. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The firm has a market cap of $25.33 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.